Liver-specific activities of FGF19 require Klotho beta
- PMID: 17627937
- DOI: 10.1074/jbc.M704244200
Liver-specific activities of FGF19 require Klotho beta
Abstract
Hepatocyte function is regulated by members of the fibroblast growth factor (FGF) family of proteins, but little is known about the specific molecular mechanisms of this endocrine pathway. FGF19 regulates bile acid homeostasis and gall bladder filling; FGF19 binds only to FGF receptor 4 (FGFR4), but its liver-specific activity cannot be explained solely by the distribution of this receptor. Although it has been suggested that Klotho beta (KLB) may have a role in mediating FGF19 activity, we have provided for the first time definitive evidence that KLB is required for FGF19 binding to FGFR4, intracellular signaling, and downstream modulation of gene expression. We have shown that FGFR4 is widely distributed in mouse, whereas KLB distribution is more restricted. Liver was the only organ in which both genes were abundantly expressed. We show that in mice, FGF19 injection triggers liver-specific induction of c-Fos and repression of CYP7A1. The tissue-specific activity of FGF19 supports the unique intersection of KLB and FGFR4 distribution in liver. These studies define KLB as a novel FGFR4 coreceptor required for FGF19 liver specific functions.
Similar articles
-
Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB.PLoS One. 2012;7(3):e33870. doi: 10.1371/journal.pone.0033870. Epub 2012 Mar 19. PLoS One. 2012. PMID: 22442730 Free PMC article.
-
Glycosylation of fibroblast growth factor receptor 4 is a key regulator of fibroblast growth factor 19-mediated down-regulation of cytochrome P450 7A1.Hepatology. 2010 Aug;52(2):656-66. doi: 10.1002/hep.23708. Hepatology. 2010. PMID: 20683963
-
FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways.PLoS One. 2011 Mar 18;6(3):e17868. doi: 10.1371/journal.pone.0017868. PLoS One. 2011. PMID: 21437243 Free PMC article.
-
Targeting the FGF19-FGFR4 pathway for cholestatic, metabolic, and cancerous diseases.J Intern Med. 2024 Mar;295(3):292-312. doi: 10.1111/joim.13767. Epub 2024 Jan 11. J Intern Med. 2024. PMID: 38212977 Review.
-
Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.Curr Cancer Drug Targets. 2019;19(1):17-25. doi: 10.2174/1568009618666180319091731. Curr Cancer Drug Targets. 2019. PMID: 29557750 Review.
Cited by
-
The fibroblast growth factor-Klotho axis at molecular level.Open Life Sci. 2023 Oct 27;18(1):20220655. doi: 10.1515/biol-2022-0655. eCollection 2023. Open Life Sci. 2023. PMID: 37941788 Free PMC article. Review.
-
Bile Acids and FXR: Novel Targets for Liver Diseases.Front Med (Lausanne). 2020 Sep 11;7:544. doi: 10.3389/fmed.2020.00544. eCollection 2020. Front Med (Lausanne). 2020. PMID: 33015098 Free PMC article.
-
FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1α pathway.Cell Metab. 2011 Jun 8;13(6):729-38. doi: 10.1016/j.cmet.2011.03.019. Cell Metab. 2011. PMID: 21641554 Free PMC article.
-
Regulation of fibroblast growth factor 15/19 and 21 on metabolism: in the fed or fasted state.J Transl Med. 2016 Mar 1;14:63. doi: 10.1186/s12967-016-0821-0. J Transl Med. 2016. PMID: 26931208 Free PMC article. Review.
-
Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption.Gastro Hep Adv. 2022 Mar 30;1(3):299-312. doi: 10.1016/j.gastha.2021.12.007. eCollection 2022. Gastro Hep Adv. 2022. PMID: 39131668 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous
